



**May 08, 2026**

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Scrip Code: 543904**

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject: Intimation of Investor Conference Call for Q4FY26 & FY26 with Senior Management of Mankind Pharma Limited (“the Company”)**

---

Pursuant to Regulation 30 & 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company will host Investor Conference Call on Wednesday, May 20, 2026 at 12:00 PM (IST) for Q4FY26 and FY26.

Details of the Investor Conference Call are enclosed herewith.

The same are also being uploaded on website of the Company at [www.mankindpharma.com](http://www.mankindpharma.com).

You are requested to kindly take the same on records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Hitesh Kumar Jain**  
**Company Secretary &**  
**Compliance Officer**

**Encl.: A/a**



**Mankind Pharma Limited**  
**Earnings Call Invite | Q4 & FY26**

You are cordially invited to the Earnings Call,  
Scheduled on **Wednesday, 20<sup>th</sup> May 2026, at 12:00 PM IST,**  
To discuss Q4 & FY26 business performance and results:

The details of the earnings call are as below:

Earnings Call Details	
<b>Date</b>	Wednesday, 20 <sup>th</sup> May 2026
<b>Time</b>	12:00 PM – 01:00 PM IST
<b>Zoom Call</b>	<a href="https://us06web.zoom.us/webinar/register/WN_gjCF6TrYR9eK24zP-RYSZQ">https://us06web.zoom.us/webinar/register/WN_gjCF6TrYR9eK24zP-RYSZQ</a>

**Management will be represented by:**

- Mr. Rajeev Juneja – Vice Chairman & Managing Director
- Mr. Sheetal Arora – Chief Executive Officer & Whole Time Director
- Mr. Arjun Juneja - Chief Operating Officer
- Mr. Sudipta Roy – Senior President – Sales & Marketing
- Mr. Ashutosh Dhawan – Global Chief Financial Officer
- Mr. Prakash Agarwal – President (Strategy)
- Mr. Abhishek Agarwal – Head - Investor Relations & Strategy

For details, please contact:

<b>Mankind Pharma Limited</b> <b>Abhishek Agarwal</b> E: <a href="mailto:Investor.relations@mankindpharma.com">Investor.relations@mankindpharma.com</a> , T: 011 – 46846700	<b>Adfactors PR</b> <b>Snighter Albuquerque / Smit Shah</b> E: <a href="mailto:Snighter.albuquerque@adfactorspr.com">Snighter.albuquerque@adfactorspr.com</a> / <a href="mailto:smit.shah@adfactorspr.com">smit.shah@adfactorspr.com</a> , M: +91 9870789596
--	--